First-pass metabolism, also known as presystemic metabolism, describes the biotransformation of a drug that occurs before it reaches the systemic circulation. When a drug is absorbed from the gastrointestinal tract, it travels via the portal vein to the liver before being distributed to the rest of the body. The liver contains high concentrations of drug-metabolizing enzymes, particularly cytochrome P450 isoforms, which can extensively metabolize drugs during this initial pass. The gut wall also contributes through the action of CYP3A4 and other enzymes in enterocytes.
The Hepatic Portal System
After oral administration, drug molecules enter the enterocytes lining the small intestine, where some metabolism may occur before the drug even reaches the portal circulation. The portal vein then carries the remaining drug from the gastrointestinal tract to the liver. Within the liver, hepatocytes extract and metabolize a fraction of the drug before it passes through the hepatic veins into the inferior vena cava and then to the systemic circulation. The fraction of absorbed drug that escapes this presystemic metabolism and reaches the systemic circulation intact is called the oral bioavailability (F) .
The extraction ratio of the liver determines the magnitude of first-pass metabolism. A drug with a high extraction ratio, such as lidocaine or propranolol, is extensively metabolized during the first pass, resulting in low oral bioavailability. A drug with a low extraction ratio, such as warfarin, undergoes minimal presystemic metabolism, and its bioavailability is high. Drugs with extraction ratios between 0.3 and 0.7 show intermediate behavior, and their bioavailability can be influenced by changes in hepatic blood flow or enzyme activity.
Impact on Oral Drug Design
First-pass metabolism poses a significant challenge to oral drug development. If a drug undergoes extensive presystemic metabolism, the oral dose must be substantially larger than the intravenous dose to achieve equivalent plasma concentrations, or the drug may be unsuitable for oral administration altogether. Medicinal chemists address this challenge through structural modifications that increase metabolic stability, such as introducing steric hindrance near metabolically vulnerable sites or replacing labile functional groups with more stable moieties.
Strategies to Bypass First-Pass Metabolism
Several routes of administration circumvent the portal circulation entirely, avoiding first-pass metabolism. Sublingual administration places the drug under the tongue, where it is absorbed directly into the lingual vein, which drains into the superior vena cava and bypasses the liver. Nitroglycerin is administered sublingually precisely because its oral bioavailability would otherwise be negligible. Buccal administration uses the cheek mucosa similarly, with the drug absorbed into the facial vein.
Transdermal delivery provides another route that avoids first-pass metabolism. Drugs penetrate the skin and enter the systemic circulation directly through the dermal capillary network. Transdermal patches for fentanyl, nicotine, and hormone replacement therapy rely on this principle. Rectal administration partially bypasses first-pass metabolism, as the lower rectal veins drain into the systemic circulation, though the upper rectum drains into the portal system, making the bioavailability of rectal drugs variable and incomplete.
Prodrugs
An ingenious strategy for dealing with first-pass metabolism is the prodrug approach. A prodrug is a pharmacologically inactive derivative of an active drug that is designed to undergo enzymatic or chemical conversion to the active form after administration. Prodrugs can improve oral bioavailability by enhancing metabolic stability or by targeting drug-metabolizing enzymes to release the active moiety. Enalapril, for example, is an ester prodrug that is hydrolyzed to enalaprilat after absorption; the prodrug form has better oral bioavailability than the active metabolite.
Clinical Implications
First-pass metabolism has important clinical consequences beyond bioavailability. Drugs that undergo extensive first-pass metabolism are susceptible to interactions with food and other drugs that alter gastrointestinal motility, blood flow, or enzyme activity. Grapefruit juice inhibits intestinal CYP3A4, increasing the bioavailability of affected drugs and potentially causing toxicity. Hepatic disease, particularly cirrhosis, can reduce first-pass metabolism, leading to higher systemic drug levels and increased risk of adverse effects. Cigarette smoking induces CYP1A2 activity but does not directly affect first-pass metabolism for most drugs.
Clinicians must consider first-pass metabolism when selecting a route of administration, choosing a dose, and predicting the magnitude of drug-drug interactions. The concept also underpins the rationale for alternative routes of delivery when oral therapy is inadequate.
